Company profile
Producing elegant treatments for complex diseases | ikarovec
Ikarovec is a pre-clinical phase gene therapy company. Our programmes are aimed at treating common eye diseases, restoring sight and preventing blindness.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
MA | Transaction MzQ0MDIzODQ0NGFkaXF6a2N4 | Paper/PDF filed
Published 28 Oct 2024 06:45
SH08 | Transaction MzQ0MDcxOTM2MGFkaXF6a2N4 | Paper/PDF filed
Published 28 Oct 2024 06:44
RESOLUTIONS | Transaction WURFNDZIRkxhZGlxemtjeA | Paper/PDF filed
Published 28 Oct 2024 06:40
SH01 | Transaction MzQ0MTAyOTY5NWFkaXF6a2N4
Published 26 Oct 2024 09:58
AP01 | Transaction MzQ0MDI3NjcyOWFkaXF6a2N4
Published 21 Oct 2024 09:47
AP01 | Transaction MzQ0MDIzODU0MWFkaXF6a2N4
Published 20 Oct 2024 01:23
CS01 | Transaction MzQzMzA4MzE1MWFkaXF6a2N4
Published 22 Aug 2024 10:06
AP01 | Transaction MzQzMTY0NzExOGFkaXF6a2N4
Published 08 Aug 2024 18:03
Company registered at Companies House
1 May 2024 to 31 Mar 2026
The development of gene therapies holds immense significance for medical innovation. Yet, the realization of their full therapeutic impact hinges on the urgent need for technological advancements that can further improve drug product (DP) quality and efficacy. Formulation, the penultimate operation prior to final fill, is crucial for robust stability that...
1 Jul 2020 to 31 Mar 2023
"Age-related macular degeneration (AMD) is an eye condition affecting the central part of the retina (the macula), which can make it difficult for patients to read, drive or recognise people's faces. The wet form of AMD (wAMD) can develop quickly, causing serious changes to central vision in a short period of time -- over days or weeks as the retina start...
